IMP-1 inhibits renal cell carcinoma 786-O cell growth by targeting EphrinB2 signaling pathway. Braz. J. Pharm. Sci. [Internet]. 2023 Jun. 22 [cited 2024 Dec. 26];59:e22102. Available from: https://revistas.usp.br/bjps/article/view/213468